logo

Albireo Pharma, Inc. (ALBO)



Trade ALBO now with
  Date
  Headline
10/25/2022 12:04:50 PM Wedbush Reiterates Albireo Pharma, Inc. (ALBO) At Outperform With $54 Price Target
10/17/2022 9:24:23 AM Wedbush Reiterates Albireo Pharma, Inc. (ALBO) At Outperform With $54 Price Target
10/11/2022 7:30:10 AM Albireo Reports Positive Topline Data From Phase 3 Trial Of Bylvay In Alagille Syndrome
9/14/2022 4:38:59 PM Wedbush Reiterates Albireo Pharma, Inc. (ALBO) At Outperform With $61 Price Target
5/17/2022 10:23:30 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) FY23 Rev. Estimate To 89.0 M From 108.0 M
5/17/2022 10:23:15 AM Wedbush Is Raising Albireo Pharma, Inc. (ALBO) Q4 23 Rev. Estimate To 28.3 M From 27.2 M
5/17/2022 10:23:03 AM Wedbush Is Lowering Albireo Pharma, Inc. (ALBO) Q3 23 Rev. Estimate To 22.8 M From 27.1 M
5/17/2022 10:22:49 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q2 23 Rev. Estimate To 19.6 M From 26.9 M
5/17/2022 10:22:37 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q1 23 Rev. Estimate To 18.3 M From 26.8 M
5/17/2022 10:22:21 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) FY22 Rev. Estimate To 43.3 M From 58.1 M
5/17/2022 10:22:08 AM Wedbush Is Lowering Albireo Pharma, Inc. (ALBO) Q4 22 Rev. Estimate To 17.6 M From 27.3 M
5/17/2022 10:21:44 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q3 22 Rev. Estimate To 10.8 M From 14.9 M
5/17/2022 10:21:27 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q2 22 Rev. Estimate To 8.1 M From 9.2 M
5/17/2022 10:21:04 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) FY23 Estimate To -2.91 From -0.62
5/17/2022 10:20:50 AM Wedbush Is Lowering Albireo Pharma, Inc. (ALBO) Q4 23 Estimate To -0.51 From -0.18